Recon: J&J, BMS and AstraZeneca appeal IRA court losses; Swiss biotech Asceneuron raises $100M to develop Alzheimer’s drug

• What to know about Trump VP pick J.D. Vance’s health care views and investments (STAT)
• Vertex sues U.S. government over access to fertility support services for Casgevy patients (STAT)
• Pharma's 340B Legal Disputes Over Contract Pharmacies May Get A Boost With Chevron Ruling (Pink Sheet)
• Fatty Liver Disease Drug Approval Opens New Patient Population In Imaging Market (Pink Sheet)
• J&J, BMS and AstraZeneca strike back in appeals after IRA litigation losses (Fierce Pharma)
• Umpteenth time’s a charm? Lawmakers try to block DTC drug ad tax deductions yet again (Fierce Pharma)

• Novo owner backs Swiss biotech Asceneuron in $100 million round (Reuters) (Endpoints)
• U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer (STAT)
• German biotech CatalYm raises $150M to repurpose obesity target for cancer (Endpoints)
• Japan Makes Renewed Policy Efforts To Fill 'Drug Gap' (Pink Sheet)
• Eleven New Drugs Filed In EU; Sipavibart & Dorocubicel Win Fast-Track Status (Pink Sheet)
• EMA Tightens Clock-Stop Rules To Address Impact On Drug Approval Timelines (Pink Sheet)
• Pilot Shows EU Needs A ‘Robust’ Shortage Signaling System for ‘Critical’ Drugs (Pink Sheet)
• China Market For Medtech: Opportunity Or Headache? (MedTech Insight)
• UK Government Accentuates Role Of Medtech As It Orders Review Of NHS (MedTech Insight)
• Second malaria vaccine launched in Ivory Coast in new milestone (Reuters)

• Roche looks to have a competitive GLP-1 drug (STAT)
• A teenager faced constant seizures. Could a drug developed just for him stop them? (Endpoints)
• Scorpion raises $150M with sights on the next wave of targeted therapies (Endpoints)
• Bain-backed Cardurion raises $260M to fund ex-Imara drug, buy more cardio assets (Endpoints)
• After last year's ImmunoGen pact, Vertex finds another conditioning agent partner in Orum (Endpoints)
• SOTIO, Biocytogen to jointly develop antibodies; Pliant's mid-stage liver disease data (Endpoints)
• Exclusive: Kins raises $7M to expand in-home and virtual physical therapy (Endpoints)

• FDA creates communication ‘super office’ at CDRH (MedTech Dive)
• J&J, Abbott and Intuitive start medtech earnings season (MedTech Dive)
• Device Center Announces Organizational Changes, Including New Marketing Division (MedTech Insight)
• AI Act Is Officially Published: Implementation Challenges Ahead For Medtech (MedTech Insight)

• Sanford Health aims to shake off a run of failed deals by snapping up a $3 billion Wisconsin health system (STAT)
• A cancer care startup is making a new bet with payers and providers: only pay if it works (STAT)
• Q&A: Jefferies analyst Brian Tanquilut talks Walgreens’ retreat from primary care and what’s sinking retailers’ healthcare bets (Endpoints)
• Slimmed-Down Obesity Drug Coverage In Medicare: First Step Or False Start? (Endpoints)